Novo to Build $6 Billion Plant as Obesity Drug Demand Surges
- Danish company has struggled to keep up with demand for Wegovy
- New site will make GLP-1 products and other medications
This article is for subscribers only.
Novo Nordisk A/S will invest more than 42 billion kroner ($6 billion) to expand its manufacturing facilities as it fights to maintain dominance of a weight-loss market that’s expected to hit $100 billion by 2030.
Work will begin this year on a new 170,000 square-meter factory at the company’s existing facilities in Kalundborg, Denmark, according a statement on Friday. Part of the investment is included in the 25 billion-krone capital expenditure the company already announced for this year; the rest will come over the next six years.